ABSTRACT Aim To evaluate the clinical and microbiological effects of a Limosilactobacillus reuteri ‐based probiotic as an adjunct to subgingival instrumentation in untreated periodontitis patients with diabetes. Methods A 6‐month, randomised, triple‐blinded clinical trial was conducted involving 40 patients, receiving steps 1 and 2 of periodontal therapy, including subgingival instrumentation, and randomised to receive tablets containing L. reuteri or placebo, for 3 months. Clinical and microbiological outcomes as well as glycosylated haemoglobin (HbA1c) concentrations were evaluated at baseline and at 3 and 6 months after therapy. Results At 6 months, both groups showed statistically significant reductions in the primary outcome (mean probing depth), with reductions of 0. 9 mm in the probiotic group and 0. 8 mm in the placebo group, with no significant differences between them. Both groups exhibited reductions in HbA1c levels after 6 months, more in the probiotic group (−0. 6% vs. –0. 1%), with statistically significant inter‐group differences (−0. 5%; 95% confidence interval −1. 0; 0. 0; p < 0. 001). Microbiological outcomes were similar. Conclusions The adjunctive use of a L. reuteri ‐based probiotic did not provide additional clinical or microbiological benefits, compared to placebo, following subgingival instrumentation in patients with periodontitis and diabetes. However, statistically significant differences in HbA1c levels were observed, with larger reductions in the probiotic group, suggesting a potential systemic benefit. Trial Registration: The protocol was approved by the Clinical Research Ethics Committee (CEIC) of Hospital Clínico de San Carlos (internal code 19/101‐RX) and registered a priori in ClinicalTrials. gov (identifier NCT04069611)
Bujaldón et al. (2025) studied this question.